EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium

Joanna Grudzinska-Goebel, Manuela Braun, Lin-Zhi Chen, Swati Gupta, Sabine Lohmann, Pedro Morais, Tao Niu, Edit Tarcsa, Sophie Tourdot, Amir S Youssef, Vibha Jawa

Nucleic Acid Therapeutics · 01.12.2025 · 35 (6) · 261-279

DOI: 10.1177/21593337251387423 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, erschienen am 01.12.2025. Verfasst von Joanna Grudzinska-Goebel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Preclinical Development, Pharmaceuticals R&D, Bayer AG, Berlin, Germany. Hauptthemen laut MEDLINE: RNA, Small Interfering, RNA, Messenger, Oligonucleotides, Antisense, Nanoparticles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 194 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of nucleic acid (NA) therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), which are usually delivered directly, and messenger RNAs (mRNAs), which are typically encapsulated in lipid nanoparticles (LNPs), marks a transformative era in precision medicine. While these therapies offer precise approaches for gene regulation or expression, they can trigger unwanted innate and/or adaptive immune responses that can either have no significant impact or adversely affect treatment efficacy and/or patient safety. Consequently, therapies where an adaptive immune response is desired, such mRNA/LNP-based vaccines against infectious diseases or cancer are out of scope of this article. In the present work, the Innovation and Quality Consortium Nucleic Acids Immunogenicity Working Group examines how the various components of NA-based therapies might contribute to their immunogenic potential and describes risk mitigation strategies through product design adaptations during early development stages. In addition, a comprehensive immunogenicity risk assessment framework is described, allowing to effectively define a tailored clinical testing strategy for different NA modalities with varying immunogenicity (IG) consequences. A streamlined monitoring strategy is recommended when minimal impact is expected, whereas extensive testing is suggested when safety concerns arise. Overall, these recommendations ensure that safe and effective NA-based therapies reach patients with an appropriate assessment of the IG potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingRNA, MessengerOligonucleotides, AntisenseNanoparticlesHumansRisk AssessmentLipidsLiposomes

Stichwörter der Autor:innen

ASOSSOimmunogenicityimmunogenicity risk assessmentmRNA LNPnucleic acidoligonucleotidesiRNA

Substanzen

RNA, Small InterferingRNA, MessengerOligonucleotides, AntisenseLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Preclinical Development, Pharmaceuticals R&D, Bayer AG, Berlin, Germany.
  • Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
  • Abbvie, Irvine, California, USA.
  • Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
  • Preclinical Development, Pharmaceuticals R&D, Bayer AG, Wuppertal, Germany.
  • Quantitative Clinical Pharmacology, Sarepta Therapeutics, Cambridge, Massachusetts, USA.

Zitieren

APA

Grudzinska-Goebel, J., Braun, M., Chen, L. Z., Gupta, S., Lohmann, S., Morais, P., Niu, T., Tarcsa, E., Tourdot, S., Youssef, A. S., & Jawa, V. (2025). Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium. Nucleic Acid Therapeutics, 35(6), 261-279. https://doi.org/10.1177/21593337251387423

Vancouver

Grudzinska-Goebel J, Braun M, Chen LZ, Gupta S, Lohmann S, Morais P, et al. Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium. Nucleic Acid Therapeutics. 2025;35(6):261-279. doi:10.1177/21593337251387423

BibTeX
@article{GrudzinskaGoebel2025,
  author = {Grudzinska-Goebel, Joanna and Braun, Manuela and Chen, Lin-Zhi and Gupta, Swati and Lohmann, Sabine and Morais, Pedro and Niu, Tao and Tarcsa, Edit and Tourdot, Sophie and Youssef, Amir S and Jawa, Vibha},
  title = {Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  volume = {35},
  number = {6},
  pages = {261--279},
  doi = {10.1177/21593337251387423}
}
Kostenlos starten →